Cargando…

Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study

Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), has emerged as a prominent global cause of chronic liver disease and is increasingly recognized as associated with atherosclerotic vascular illness, consolidating its position along tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Adelaida, Negrea, Mihai Octavian, Cipăian, Călin Remus, Boicean, Adrian, Mihaila, Romeo, Rezi, Cristina, Cristinescu, Bianca Andreea, Berghea-Neamtu, Cristian Stefan, Popa, Mirela Livia, Teodoru, Minodora, Stoia, Oana, Neamtu, Bogdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572783/
https://www.ncbi.nlm.nih.gov/pubmed/37830733
http://dx.doi.org/10.3390/healthcare11192696
_version_ 1785120313262997504
author Solomon, Adelaida
Negrea, Mihai Octavian
Cipăian, Călin Remus
Boicean, Adrian
Mihaila, Romeo
Rezi, Cristina
Cristinescu, Bianca Andreea
Berghea-Neamtu, Cristian Stefan
Popa, Mirela Livia
Teodoru, Minodora
Stoia, Oana
Neamtu, Bogdan
author_facet Solomon, Adelaida
Negrea, Mihai Octavian
Cipăian, Călin Remus
Boicean, Adrian
Mihaila, Romeo
Rezi, Cristina
Cristinescu, Bianca Andreea
Berghea-Neamtu, Cristian Stefan
Popa, Mirela Livia
Teodoru, Minodora
Stoia, Oana
Neamtu, Bogdan
author_sort Solomon, Adelaida
collection PubMed
description Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), has emerged as a prominent global cause of chronic liver disease and is increasingly recognized as associated with atherosclerotic vascular illness, consolidating its position along traditional cardiovascular risk factors. Individuals with MASLD exhibit a combination of metabolic syndrome risk factors, carotid atherosclerosis, and increased arterial stiffness, hinting at shared pathogenesis. In this study, we aim to explore liver involvement and arterial stiffness within metabolic syndrome. We enrolled 75 patients (30 male and 45 female) with either liver steatosis on conventional ultrasound, altered liver function tests, or the presence of cardiometabolic risk factors after excluding liver pathology other than MASLD. Clinical evaluation, laboratory measurements, abdominal and carotid ultrasounds, vibration-controlled transient elastography (VCTE, Fibroscan), and assessment with the Arteriograph (Tensiomed) were performed. The 26 patients diagnosed with MetS had significantly higher liver involvement as quantified via the hepatic steatosis index (HSI), Fibrosis-4 (FIB4), aspartate aminotransferase to platelet ratio index (APRI) category, and VCTE measurements, as well as Agile 3+ and Agile 4 scores which use a combination of clinical and laboratory parameters together with results obtained from VCTE to reflect the probability of advanced liver fibrosis or cirrhosis. Patients with MetS also exhibited more pronounced vascular involvement as quantified via arterial stiffness measurements and CIMT (carotid intima–media thickness). We applied a two-step clustering algorithm to enhance our analysis, which gave us pertinent insight into the interplay between metabolic syndrome elements and typologies of hepatic steatosis and arterial stiffness degrees. Notably, of the three obtained clusters, the cluster showing increased levels of hepatic steatosis and arterial stiffness also exhibited the highest prevalence of metabolic syndrome and its constituting components. The results have significant clinical implications, advocating for a comprehensive diagnostic approach when MetS or MASLD is suspected.
format Online
Article
Text
id pubmed-10572783
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105727832023-10-14 Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study Solomon, Adelaida Negrea, Mihai Octavian Cipăian, Călin Remus Boicean, Adrian Mihaila, Romeo Rezi, Cristina Cristinescu, Bianca Andreea Berghea-Neamtu, Cristian Stefan Popa, Mirela Livia Teodoru, Minodora Stoia, Oana Neamtu, Bogdan Healthcare (Basel) Article Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), has emerged as a prominent global cause of chronic liver disease and is increasingly recognized as associated with atherosclerotic vascular illness, consolidating its position along traditional cardiovascular risk factors. Individuals with MASLD exhibit a combination of metabolic syndrome risk factors, carotid atherosclerosis, and increased arterial stiffness, hinting at shared pathogenesis. In this study, we aim to explore liver involvement and arterial stiffness within metabolic syndrome. We enrolled 75 patients (30 male and 45 female) with either liver steatosis on conventional ultrasound, altered liver function tests, or the presence of cardiometabolic risk factors after excluding liver pathology other than MASLD. Clinical evaluation, laboratory measurements, abdominal and carotid ultrasounds, vibration-controlled transient elastography (VCTE, Fibroscan), and assessment with the Arteriograph (Tensiomed) were performed. The 26 patients diagnosed with MetS had significantly higher liver involvement as quantified via the hepatic steatosis index (HSI), Fibrosis-4 (FIB4), aspartate aminotransferase to platelet ratio index (APRI) category, and VCTE measurements, as well as Agile 3+ and Agile 4 scores which use a combination of clinical and laboratory parameters together with results obtained from VCTE to reflect the probability of advanced liver fibrosis or cirrhosis. Patients with MetS also exhibited more pronounced vascular involvement as quantified via arterial stiffness measurements and CIMT (carotid intima–media thickness). We applied a two-step clustering algorithm to enhance our analysis, which gave us pertinent insight into the interplay between metabolic syndrome elements and typologies of hepatic steatosis and arterial stiffness degrees. Notably, of the three obtained clusters, the cluster showing increased levels of hepatic steatosis and arterial stiffness also exhibited the highest prevalence of metabolic syndrome and its constituting components. The results have significant clinical implications, advocating for a comprehensive diagnostic approach when MetS or MASLD is suspected. MDPI 2023-10-09 /pmc/articles/PMC10572783/ /pubmed/37830733 http://dx.doi.org/10.3390/healthcare11192696 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Solomon, Adelaida
Negrea, Mihai Octavian
Cipăian, Călin Remus
Boicean, Adrian
Mihaila, Romeo
Rezi, Cristina
Cristinescu, Bianca Andreea
Berghea-Neamtu, Cristian Stefan
Popa, Mirela Livia
Teodoru, Minodora
Stoia, Oana
Neamtu, Bogdan
Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title_full Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title_fullStr Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title_full_unstemmed Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title_short Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
title_sort interactions between metabolic syndrome, masld, and arterial stiffening: a single-center cross-sectional study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572783/
https://www.ncbi.nlm.nih.gov/pubmed/37830733
http://dx.doi.org/10.3390/healthcare11192696
work_keys_str_mv AT solomonadelaida interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT negreamihaioctavian interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT cipaiancalinremus interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT boiceanadrian interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT mihailaromeo interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT rezicristina interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT cristinescubiancaandreea interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT bergheaneamtucristianstefan interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT popamirelalivia interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT teodoruminodora interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT stoiaoana interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy
AT neamtubogdan interactionsbetweenmetabolicsyndromemasldandarterialstiffeningasinglecentercrosssectionalstudy